This market research study presents a detailed segmentation of the global postmenopausal vaginal atrophy (PVA) market by drug class (topical estrogen and systemic estrogen) and by geography (Americas, APAC, and EMEA). The key leading vendors in the market are Pfizer, Allergen, Shionogi, Novo Nordisk, and Teva Pharmaceutical.
Technavio’s market research analysts estimate the global PVA drugs market to grow at a CAGR of around 7% between 2016 and 2020. Vaginal atrophy refers to the decrease in the production of estrogen after menopause, leading to thinning, drying, and reduced elasticity of the vaginal tissues. Over 40% of post-menopausal women experience atrophic vaginitis symptoms such as itching, burning, dryness, and dyspareunia. Of late, hormone replacement therapy (HRT) and estrogen creams are the available treatments for PVA. The Americas is the largest revenue-contributing region in the PVA drugs market, occupying around 86% of the total market share. Much of this region’s growth comes from the increasing awareness about the benefits of PVA products encourages people to opt for this treatment.
The new market research report from Technavio provides a breakdown and analysis of the PVA segments by technology.
“One of the latest trends in the global PVA drugs market is the paradigm shift to non-estrogenic therapies. Non-estrogenic therapies in PVA treatment are a paradigm shift from systemic estrogen treatments such as creams, patches, and gels. Moreover, the launch of late-stage pipeline products expected to shift the attention from vaginal creams and OTC classes toward vaginal tablets and oral therapies. Therefore, the growing adoption of non-estrogenic therapies will propel the growth of this market segment during the forecast period,” says Barath Palada, Lead Analyst, Pharma, Technavio Research
The topical estrogen segment leads the PVA drugs market, accounting for almost 60% of the market share. Topical estrogen supplies include vaginal creams, vaginal tablet, and vaginal ring to drive this market segment’s growth in the coming years. Vaginal cream is the most widely used and preferred mode of treatment for PVA. It is more convenient to use than vaginal rings and is associated with fewer adverse events than oral estrogen therapy (systemic).
The key vendors in the global PVA drugs market include Pfizer, Allergen, Shionogi, Novo Nordisk, and Teva Pharmaceutical. The market is highly competitive due to the presence of both local and international drug manufacturers. The market is open to new players and has a lot of opportunities for growth. The competitive environment is expected to increase in due to the product extensions, new products, and new applications of the products and services provided.
A more detailed analysis is available in the Technavio report, Global PVA Drugs Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
